Myriad Genetics Inc (MYGN)
Cash ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 102,400 | 99,900 | 92,400 | 96,900 | 132,100 | 76,000 | 102,800 | 53,600 | 56,900 | 110,700 | 105,200 | 165,200 | 258,400 | 295,200 | 118,400 | 148,900 | 117,000 | 118,300 | 163,700 | 121,000 |
| Short-term investments | US$ in thousands | 0 | 0 | 4,900 | 7,400 | 8,800 | 10,300 | 18,800 | 25,100 | 58,000 | 82,500 | 99,900 | 103,200 | 81,400 | 70,900 | 46,000 | 27,200 | 33,700 | 42,100 | 54,100 | 60,500 |
| Total current liabilities | US$ in thousands | 164,100 | 154,300 | 148,900 | 146,100 | 155,900 | 209,300 | 221,100 | 143,300 | 137,200 | 129,100 | 119,700 | 166,000 | 204,300 | 203,200 | 271,000 | 149,000 | 145,900 | 133,700 | 147,000 | 113,200 |
| Cash ratio | 0.62 | 0.65 | 0.65 | 0.71 | 0.90 | 0.41 | 0.55 | 0.55 | 0.84 | 1.50 | 1.71 | 1.62 | 1.66 | 1.80 | 0.61 | 1.18 | 1.03 | 1.20 | 1.48 | 1.60 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($102,400K
+ $0K)
÷ $164,100K
= 0.62
The cash ratio of Myriad Genetics Inc has fluctuated over the years based on the provided data. The cash ratio, which measures a company's ability to cover its short-term liabilities with its cash and cash equivalents, stood at 1.60 as of March 31, 2020, indicating that the company had $1.60 in cash and cash equivalents for every dollar of current liabilities.
The cash ratio decreased to 0.61 as of June 30, 2021, before rebounding to a high of 1.80 as of September 30, 2021. This improvement in the cash ratio suggests that the company had increased its cash reserves relative to its short-term obligations during that period.
However, the cash ratio declined again to 0.41 as of September 30, 2023, before recovering slightly to 0.71 as of March 31, 2024. The decreasing trend in the cash ratio during this period may indicate potential liquidity challenges or a decreased ability to cover short-term obligations with cash on hand.
Overall, fluctuations in the cash ratio of Myriad Genetics Inc suggest variations in the company's liquidity position and its ability to meet short-term obligations using cash and cash equivalents. It is essential for stakeholders to monitor these changes to assess the company's financial health and liquidity management.
Peer comparison
Dec 31, 2024